Source: China – South China Morning PostPfizer’s Covid-19 pill is one step closer to clinical use in China, with state-owned China Meheco Corp securing a deal with Pfizer to commercialise the drug within the year.The Chinese company had signed a contract with Pfizer and was authorised to supply Paxlovid in China during the 2022 agreement period, China Meheco said in a statement on Wednesday night.Last month, China’s drug regulator conditionally approved Paxlovid to treat adults with mild to moderate Covid-19 who had a high risk of…Read More